Figure 5
Olaparib treatment blocks E2-mediated growth of MCF-7 and BT474 cells and inhibits expression of PDZK1, IGF-1R, and cyclin D1. MCF-7 (a) or BT474 (b) cells were stimulated with 1 nM E2 for 48 h in the absence or presence of the indicated olaparib concentrations. Cell viability was then assessed using a MTT assay. ¶Difference from viability values of cells that did not receive olaparib; p < 0.05. §Difference from viability values of cells that were treated with E2 alone; p < 0.05. c MCF-7 cells were treated with E2 for 48 h in the absence or presence of increasing concentrations of olaparib after which protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, IGF-1R, or GAPDH. d MCF-7 cells were treated with E2 for 24 h in the presence of 5 μM olaparib. Total RNA was prepared and subjected to reverse transcription followed by quantitative PCR with primers specific to human PDZK1, IGF-1R or β-actin. §Difference from E2-treated cells; p < 0.05.